Association Between Blunted Heart Rate Response to Dipyridamole and Myocardial Ischemia in Diabetic Patients as Compared With Nondiabetic Patients

Document Type: Original Article

Authors

1 Rajaie Cardiovascular, Medical, and Research Center, Iran University of Medical Sciences, Tehran, IR Iran.

2 Rasule Akram General Hospital, Iran University of Medical Sciences, Tehran, IR Iran.

Abstract

Background: Blunted heart rate response (BHR) during dipyridamole stress testing has been reported to be related to higher cardiac death. This study was performed to assess the association between BHR and perfusion abnormalities in diabetic patients undergoing dipyridamole stress ECG-gated myocardial perfusion imaging (MPI) as compared with nondiabetic patients.
Methods: A total of 2172 subjects (1602 women and 570 men) at a mean age of 61 ± 11 years who were referred for MPI to our department were studied. The subjects were divided into 2 groups on the basis of the presence or absence of diabetes mellitus (849 diabetic vs 1323 nondiabetic subjects).
Results: Dipyridamole-related BHR was noted in 471 (67.7%) patients, demonstrating a significantly higher incidence in the diabetic patients than in the nondiabetic subjects (P < 0.05). Both basal systolic and peak systolic blood pressures were significantly higher in the patients with diabetes mellitus (P < 0.05). However, no significant difference was noted in the number of segments with perfusion abnormalities in patients with BHR as compared with the subjects with a normal hemodynamic response, neither in the diabetic nor in the nondiabetic subjects.
Conclusions: The results of our study suggest that the presence of myocardial perfusion abnormalities and left ventricular dysfunction is not related to abnormal heart rate response during dipyridamole stress testing, neither in diabetic nor in nondiabetic subjects. The incidence of BHR to dipyridamole is significantly higher in diabetic patients, however. 

Keywords


1. Mathur S, Shah AR, Ahlberg AW, Katten
DM, Heller GV. Blunted heart rate response
as a predictor of cardiac death in patients
undergoing vasodilator stress technetium-
99m sestamibi gated SPECT myocardial
perfusion imaging. J Nucl Cardiol.
2010;17(4):617-24.
2. Lee KH, Yoon JK, Lee MG, Lee SH, Lee
WR, Kim BT. Dipyridamole myocardial
SPECT with low heart rate response
indicates cardiac autonomic dysfunction in
patients with diabetes. Journal of nuclear
cardiology. 2001;8(2):129-35.
3. Petrucci E, Mainardi LT, Balian V,
Ghiringhelli S, Bianchi AM, Bertinelli M, et
al. Assessment of Heart Rate Variability
Changes During Dipyridamole Infusion and
Dipyridamole-Induced Myocardial
Ischemia: A Time Variant Spectral
Approach1. Journal of the American College
of Cardiology. 1996;28(4):924-34.
4. Petretta M, Spinelli L, Marciano F, Vicario
ML, Testa G, Signorini A, et al. Wavelet
transform analysis of heart rate variability
during dipyridamole‐induced myocardial
ischemia: Relation to angiographic severity
and echocardiographic dyssynergy. Clinical
cardiology. 1999;22(3):201-6.
5. Lette J, Tatum JL, Fraser S, Miller DD,
Waters DD, Heller G, et al. Safety of
dipyridamole testing in 73,806 patients: the
Multicenter Dipyridamole Safety Study.
Journal of nuclear cardiology. 1995;2(1):3-
17.
6. Bhatheja R, Francis GS, Pothier CE, Lauer
MS. Heart Rate Response During< i>
Dipyridamole</i> Stress as a Predictor of
Mortality in Patients With Normal
Myocardial Perfusion and Normal
Electrocardiograms. The American journal
of cardiology. 2005;95(10):1159-64.
7. Kim YH, Lee KH, Chang HJ, Lee EJ,
Chung HW, Choi JY, et al. Depressed heart
rate response to vasodilator stress for
myocardial SPECT predicts mortality in
patients after myocardial infarction. The
International Journal of Cardiovascular
Imaging (formerly Cardiac Imaging).
2006;22(5):663-70.
8. Abidov A, Hachamovitch R, Hayes SW, Ng
CK, Cohen I, Friedman JD, et al. Prognostic
impact of hemodynamic response to
adenosine in patients older than age 55 years
undergoing vasodilator stress myocardial
perfusion study. Circulation.
2003;107(23):2894-9.
9. de Souza Leão Lima R, Machado L,
Azevedo AB, De Lorenzo A. Predictors of
abnormal heart rate response to
dipyridamole in patients undergoing
myocardial perfusion SPECT. Annals of
nuclear medicine. 2011;25(1):7-11.
10. Galinier M, Pathak A, Fourcade J,
Androdias C, Curnier D, Varnous S, et al.
Depressed low frequency power of heart rate
variability as an independent predictor of
sudden death in chronic heart failure.
European heart journal. 2000;21(6):475-82.
11. Stein PK, Barzilay JI, Chaves PHM,
Mistretta SQ, Domitrovich PP, Gottdiener
JS, et al. Novel measures of heart rate
variability predict cardiovascular mortality in older adults independent of traditional
cardiovascular risk factors: the
Cardiovascular Health Study (CHS). Journal
of cardiovascular electrophysiology.
2008;19(11):1169-74.
12. Malek H, Hedayati R, Yaghoobi N, Behnia
M, Rastgou F, Bitarafan Rajabi A, et al. The
relationship between retinopathy in diabetes
mellitus type 2 and severity and extent of
myocardial ischemia in myocardial
perfusion imaging. Iranian Heart Journal.
2013;13(4):6-14.
13. Ziegler D, Gries F, Spüler M, Lessmann F.
The epidemiology of diabetic neuropathy.
Journal of Diabetes and its Complications.
1992;6(1):49-57.
14. Fedele D, Comi G, Coscelli C, Cucinotta D,
Feldman EL, Ghirlanda G, et al. A
multicenter study on the prevalence of
diabetic neuropathy in Italy. Diabetes Care.
1997;20(5):836-43.
15. Ewing D, Campbell I, Clarke B. Mortality in
diabetic autonomic neuropathy. The Lancet.
1976;307(7960):601-3.
16. Henzlova MJ, Duvall WL, Einstein AJ,
Travin MI, Verberne HJ. ASNC imaging
guidelines for SPECT nuclear cardiology
procedures: Stress, protocols, and tracers.
Journal of Nuclear Cardiology.23(3):606-39.
17. Seret A. The number of subsets required for
OSEM reconstruction in nuclear cardiology.
European journal of nuclear medicine and
molecular imaging. 2006;33(2):231.
18. Malek H, Yaghoobi N, Hedayati R. Artifacts
in Quantitative analysis of myocardial
perfusion SPECT, using Cedars-Sinai QPS
Software. Journal of Nuclear Cardiology.
2017;24(2):534-42.
19. H Malek, N Yaghoobi, F Rastgou, A
Bitarafan-Rajabi FR, M Alvandi, M Kargar,
R Hedayati, H Amouzadeh, Sh Hosseini, H
Firoozabadi. Assessment of myocardial
viability in patients with left ventricular
dysfunction: Correlation between CT-based
attenuation correction and uncorrected
quantification analysis in
thallium201(201Tl)rest-redistribution
SPECT study. Iranian Heart Journal.
2013;13(4):15-20.
20. Johnston DL, Daley JR, Hodge DO,
Hopfenspirger MR, Gibbons RJ, editors.
Hemodynamic responses and adverse effects
associated with adenosine and dipyridamole
pharmacologic stress testing: a comparison
in 2,000 patients1995: Mayo Clinic.
21. De Lorenzo A, Lima RSL. Reduced heart
rate response to dipyridamole as a marker of
left ventricular dysfunction in diabetic
patients undergoing myocardial perfusion
scintigraphy. Clinical nuclear medicine.
2009;34(5):275.
22. Kim SB, Lee SK, Park JS, Moon DH.
Prevalence of coronary artery disease using
thallium-201 single photon emission
computed tomography among patients
newly undergoing chronic peritoneal
dialysis and its association with mortality.
American journal of nephrology.
2004;24(4):448-52.